MedTrace Logo

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1701

Last updated 2011-08-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels) coronary artery disease.

Conditions

  • Coronary Disease

Interventions

DEVICE

CoStar Paclitaxel Drug Eluting Coronary Stent System

Drug eluting stent

DEVICE

TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent

Drug eluting stent

Sponsors & Collaborators

  • Conor Medsystems

    collaborator INDUSTRY

  • Cordis Corporation

    lead INDUSTRY

Principal Investigators

  • Dean J Kereiakes, MD · The Christ Hospital, Cincinnati, Ohio

  • Mitchell W Krucoff, MD · Duke University Medical Center, Durham, NC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-01-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165035 on ClinicalTrials.gov